Search research articles
Contact Us
Filters
Showing results (11-20 of 38) with videos related to
Page
of 4
Sort By:
Molecular Neurodegeneration
|
August 30, 2023
Amyloid-β (Aβ) immunotherapy induced microhemorrhages are associated with activated perivascular macrophages and peripheral monocyte recruitment in Alzheimer's disease mice
Xavier Taylor, Isaiah M Clark, Griffin J Fitzgerald, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience
|
August 29, 2003
Apolipoprotein E markedly facilitates age-dependent cerebral amyloid angiopathy and spontaneous hemorrhage in amyloid precursor protein transgenic mice
John D Fryer, Jennie W Taylor, Ronald B DeMattos, et al.
Clinical Neuropharmacology
|
April 9, 2010
Safety and changes in plasma and cerebrospinal fluid amyloid beta after a single administration of an amyloid beta monoclonal antibody in subjects with Alzheimer disease
Eric R Siemers, Stuart Friedrich, Robert A Dean, et al.
Journal of Alzheimer'S Disease : JAD
|
January 11, 2013
Validation of assays for measurement of amyloid-β peptides in cerebrospinal fluid and plasma specimens from patients with Alzheimer's disease treated with solanezumab
D Richard Lachno, Barbara A Evert, Hugo Vanderstichele, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
July 30, 2002
Clusterin promotes amyloid plaque formation and is critical for neuritic toxicity in a mouse model of Alzheimer's disease
Ronald B DeMattos, Mark A O'dell, Maia Parsadanian, et al.
Hypertension (Dallas, Tex. : 1979)
|
March 7, 2012
Midlife blood pressure, plasma β-amyloid, and the risk for Alzheimer disease: the Honolulu Asia Aging Study
Nilay S Shah, Jean-Sébastien Vidal, Kamal Masaki, et al.
Molecular Neurodegeneration
|
October 21, 2024
Amyloid-β (Aβ) immunotherapy induced microhemorrhages are linked to vascular inflammation and cerebrovascular damage in a mouse model of Alzheimer's disease
Xavier Taylor, Harun N Noristani, Griffin J Fitzgerald, et al.
Alzheimer'S & Dementia (New York, N. Y.)
|
December 5, 2018
Central pharmacodynamic activity of solanezumab in mild Alzheimer's disease dementia
Brian A Willis, Karen Sundell, D Richard Lachno, et al.
Nature Neuroscience
|
April 10, 2002
Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model
Jean-Cosme Dodart, Kelly R Bales, Kimberley S Gannon, et al.
The Journal of Biological Chemistry
|
May 13, 2005
The low density lipoprotein receptor regulates the level of central nervous system human and murine apolipoprotein E but does not modify amyloid plaque pathology in PDAPP mice
John D Fryer, Ronald B Demattos, Lynn M McCormick, et al.
Page
of 4
Search research articles
Search
Showing results (11-20 of 38) with videos related to
Sort By:
Page
of 4
Molecular Neurodegeneration
|
August 30, 2023
Amyloid-β (Aβ) immunotherapy induced microhemorrhages are associated with activated perivascular macrophages and peripheral monocyte recruitment in Alzheimer's disease mice
Xavier Taylor, Isaiah M Clark, Griffin J Fitzgerald, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience
|
August 29, 2003
Apolipoprotein E markedly facilitates age-dependent cerebral amyloid angiopathy and spontaneous hemorrhage in amyloid precursor protein transgenic mice
John D Fryer, Jennie W Taylor, Ronald B DeMattos, et al.
Clinical Neuropharmacology
|
April 9, 2010
Safety and changes in plasma and cerebrospinal fluid amyloid beta after a single administration of an amyloid beta monoclonal antibody in subjects with Alzheimer disease
Eric R Siemers, Stuart Friedrich, Robert A Dean, et al.
Journal of Alzheimer'S Disease : JAD
|
January 11, 2013
Validation of assays for measurement of amyloid-β peptides in cerebrospinal fluid and plasma specimens from patients with Alzheimer's disease treated with solanezumab
D Richard Lachno, Barbara A Evert, Hugo Vanderstichele, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
July 30, 2002
Clusterin promotes amyloid plaque formation and is critical for neuritic toxicity in a mouse model of Alzheimer's disease
Ronald B DeMattos, Mark A O'dell, Maia Parsadanian, et al.
Hypertension (Dallas, Tex. : 1979)
|
March 7, 2012
Midlife blood pressure, plasma β-amyloid, and the risk for Alzheimer disease: the Honolulu Asia Aging Study
Nilay S Shah, Jean-Sébastien Vidal, Kamal Masaki, et al.
Molecular Neurodegeneration
|
October 21, 2024
Amyloid-β (Aβ) immunotherapy induced microhemorrhages are linked to vascular inflammation and cerebrovascular damage in a mouse model of Alzheimer's disease
Xavier Taylor, Harun N Noristani, Griffin J Fitzgerald, et al.
Alzheimer'S & Dementia (New York, N. Y.)
|
December 5, 2018
Central pharmacodynamic activity of solanezumab in mild Alzheimer's disease dementia
Brian A Willis, Karen Sundell, D Richard Lachno, et al.
Nature Neuroscience
|
April 10, 2002
Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model
Jean-Cosme Dodart, Kelly R Bales, Kimberley S Gannon, et al.
The Journal of Biological Chemistry
|
May 13, 2005
The low density lipoprotein receptor regulates the level of central nervous system human and murine apolipoprotein E but does not modify amyloid plaque pathology in PDAPP mice
John D Fryer, Ronald B Demattos, Lynn M McCormick, et al.
Page
of 4